Dose Refer to the current product Induction Dose– 2 g/kg over 2 or 5 days The dose has been defined based on Specialist information sheet for further Working Group consensus and are consistent Up to 2 additional monthly doses are allowed when recovery information. with the UK criteria supporting up to three is incomplete. doses, one month apart (UK Department of Conditions for additional dose: After 4 and 8 weeks, further The aim should be to use the Health, 2011). 2 doses allowed if inadequate response is demonstrated. A lowest dose possible that maximum of 3 doses is allowed. achieves the appropriate clinical outcome for each patient. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. References (most recent update: May 2016) Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al (2013) Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia related to Human Parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clinical Infectious Diseases, 56:968-77. Geetha D, Zachary JB, Baldo HM, Kronz JD and Kraus ES (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clinical Transplant, 14:586-91. Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Yokota-Ikeda N, et al (2013) Clinical characteristics and outcomes of 11 patients with pure red cell
Dose Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Induction Dose– 2 g/kg over 2 or 5 days Up to 2 additional monthly doses are allowed when recovery is incomplete. Conditions for additional dose: After 4 and 8 weeks, further 2 doses allowed if inadequate response is demonstrated. A maximum of 3 doses is allowed. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. The dose has been defined based on Specialist Working Group consensus and are consistent with the UK criteria supporting up to three doses, one month apart (UK Department of Health, 2011). References (most recent update: May 2016) Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al (2013) Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia related to Human Parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clinical Infectious Diseases, 56:968-77. Geetha D, Zachary JB, Baldo HM, Kronz JD and Kraus ES (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clinical Transplant, 14:586-91. Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Yokota-Ikeda N, et al (2013) Clinical characteristics and outcomes of 11 patients with pure red cell
Haematology-Ch7-Pure-red-cell-aplasia.DOCX